Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms

Nectero Medical has received FDA clearance to begin a Phase II/III clinical trial for their Nectero EAST® System, which aims to treat small- to mid-sized abdominal aortic aneurysms. &nbsp In an exciting development, Nectero Medical, a clinical-stage biotechnology company focused on improving the lives of patients with aneurysmal disease, announced that they have been granted Investigational New ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix, Inc. (Nasdaq: SNPX) has announced a collaboration with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). The study aims to evaluate the drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients. Cleveland Clinic will oversee the implementation of the clinical trial, which inclu..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 19.
  • textsms

Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Adcentrx Therapeutics Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ADRX-0706, a groundbreaking Antibody-Drug Conjugate (ADC) that targets Nectin-4 to treat advanced solid tumors. This marks the first time that Adcentrx's ADC platform has been granted FDA clearance, signaling a major milestone for the company. ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration On July 3, 2023, Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 4.
  • textsms